EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

ASPIRIN IN CARDIOVASCULAR DISEASES: AN EFFECTIVE TOOL FORPREVENTION AND TREATMENT

V. Dharani*, K. N. Priyadharshini, M. Navya Sai, R. Rikana, K. Tirumala Naik and M. Kishore Babu

ABSTRACT

Aspirin, a widely used drug with anti-inflammatory and anti-platelet properties, has demonstrated effectiveness in the prevention and treatment of cardiovascular diseases (CVD). This article provides an overview of aspirin's mechanisms of action, dosage considerations, risks, and clinical effectiveness in the context of cardiovascular health. Aspirin inhibits cyclooxygenase (COX)-1, reducing the production of thromboxane A2 and promoting vasodilation and platelet inhibition. Low doses of aspirin (75-325 mg/day) are recommended for most patients, with an initial loading dose for prompt anti-platelet effects. Risks of bleeding and gastrointestinal side effects exist, and caution is advised for individuals with a history of major bleeding or those taking blood thinners. Aspirin is beneficial in acute coronary syndrome, Kawasaki's disease, and thromboembolic stroke treatment, and it plays a significant role in secondary prevention of cardiovascular events. The use of aspirin for primary prevention requires careful consideration of individual risk factors. Further research is needed to refine dosage recommendations and explore aspirin's potential in primary prevention strategies for CVD.

Keywords: Aspirin, cardiovascular diseases, thromboembolic stroke, anti inflammatory, anti-platelet effects.

[Full Text Article] [Download Certificate]